|
at 08:16 |
|
|
On March 28, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO: ORX) successfully issued senior secured callable floating rate social bonds in an amount of SEK 500 million and with a tenor of four years (the "Bonds").
Pursuant to the terms and...
|
|
at 08:07 |
|
|
On the evening of May 5, Kexing Biopharm (stock code: 688136) announced it had obtained a "Certificate of GMP Compliance of a Manufacturer" granted by the Norwegian Medical Products Agency in accordance with the European Medicines Agency (EMA)...
|
|
at 08:05 |
|
|
Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 3:35 pm ET.
The presentation will...
|
|
at 08:05 |
|
|
Azitra, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company's platform and pipeline. The data are being presented on Friday, May 10,...
|
|
at 08:05 |
|
|
Viridian Therapeutics, Inc. , a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming...
|
|
at 08:05 |
|
|
$16.3 million in cash and cash equivalents at the end of Q1 2024 providing projected cash runway into Q1 2026
Third amendment made in Q1 to Cipla partnership results in the wind down of the PUR1900 Phase 2b study and allows for a significant...
|
|
|
